The symposium held in SIP on Oct 15 brought together nearly 50 leaders of multinational biotech companies and industry associations and officials from local government departments at provincial and municipal levels and SIP authorities. Together, they explored pathways for open innovation across the biomedical industry chain.
At the event, many companies shared their experiences of growing together with SIP, showing strong confidence in expanding investments in the park.
Jean-Christophe Pointeau, senior vice president of Pfizer and president of Pfizer China, highlighted that Jiangsu, especially Suzhou, has become a key hub for multinational pharma companies’ R&D, production and commercialization in China. “We look forward to expanding cooperation with local partners to jointly advance scientific innovation,” he said.
Eli Lilly China Senior Vice President Chen Xiaojing said Eli Lilly and Company was among the first multinationals to establish a presence in SIP and remains one of foreign investors with the largest investments in Jiangsu. Last October, Lilly announced an additional investment of US$200 million to upgrade production capacity in Suzhou.
Garret Nolan, general manager of Roche Diagnostics Asia Manufacturing and R&D Site, shared that Roche’s new project in SIP represents its largest single investment in China. The project is expected to produce over 400 products annually, with an estimated output value of RMB10 billion.
Yang Dajun, chairman of Ascentage Pharma, gave an introduction to the company’s new products and efforts in innovation.
The guests also visited SIP Exhibition Center where they gained a holistic picture of SIP’s future development plans, and toured around the Biosparc that is being built in the park. They met with the executives of 10 local hospitals to discuss possibilities of collaborating in promoting innovations and fulfilling clinical needs.
During the face-to-face discussions with the local officials, the representatives from the companies specified needs for support from local authorities, and received positive response.
The Global Innovation Partnership Program for Multinational Biomedicine Companies was launched, aimed at fostering collaboration between Suzhou and global biomedicine firms.
October 17, 2025
